On 16 December, the European Commission unveiled a package of measures to improve the health of EU citizens, while ensuring the long-term resilience and competitiveness of the health sector. The package is designed to boost biotechnology, medical innovation and cardiovascular research across the EU.
At its core is a proposed Biotech Act, aimed at moving breakthroughs faster from lab to market. The Act foresees new funding instruments, including a health biotech investment pilot with the EIB Group, and targeted support for bio-manufacturing. It aims at streamlining and accelerating cross-border clinical trial authorisations and at creating single regulatory pathways for complex, innovative products. Regulatory sandboxes are planned to support AI- and data-driven therapies, reducing compliance burdens while maintaining safety.
https://ec.europa.eu/commission/presscorner/detail/en/ip_25_3077